We can’t show the full text here under this license.
Abstract
The gut-liver axis is crucial in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).
- Key metabolites from gut bacteria, such as lipopolysaccharides and short-chain fatty acids, play an important role in MASLD.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may aid in managing MASLD by promoting weight loss and enhancing liver health.
- GLP-1 RAs are associated with restoring gut-liver axis functionality, particularly when combined with dietary changes.
- The gut microbiome may significantly influence the effectiveness of GLP-1 RA therapies for MASLD.
- Metabolites from gut bacteria can stimulate GLP-1 secretion, potentially improving metabolic health.
- Integrating dietary interventions with GLP-1 RA treatment could enhance liver health by influencing the gut microbiota and related metabolic pathways.
Simplified